NCT03096366 Does Blood Flow Restriction Training Improve Quadriceps Function After Arthroscopic Knee Surgery?
| NCT ID | NCT03096366 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Quadriceps Atrophy |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2017-11-21 |
| Primary Completion | 2022-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2017-11-21 with a primary completion date of 2022-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the effectiveness of physical therapy (PT) plus BFR training compared to PT alone (without BFR training) after ACL reconstruction in patients who require extended limited weight bearing through assessment of patient reported outcomes and functional testing. The hypothesis is that PT plus BFR training will mitigate the loss of quadriceps muscle cross-sectional area, strength, and function while also improving early clinical and functional results.
Eligibility Criteria
Inclusion Criteria: * Anterior cruciate ligament (ACL) reconstruction with concomitant meniscus or cartilage restoration procedures * Adherence to modified weight bearing status before initiation of PT * Expected participation in recreational or competitive sports after release to full activities Exclusion Criteria: * Unable to attend (or participate in) physical therapy * Pregnancy * Malignancy * Fracture * Peripheral vascular disease * History of deep vein thrombosis (DVT)
Contact & Investigator
Walter R Lowe, MD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center, Houston
Frequently Asked Questions
Who can join the NCT03096366 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 55 Years, studying Quadriceps Atrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03096366 currently recruiting?
Yes, NCT03096366 is actively recruiting participants. Contact the research team at walter.r.lowe@uth.tmc.edu for enrollment information.
Where is the NCT03096366 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT03096366 clinical trial?
NCT03096366 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Walter R Lowe, MD at The University of Texas Health Science Center, Houston. The trial plans to enroll 150 participants.